🔎 Trials Near Me

홈 › 급성 이표형 백혈병 › 펜실베이니아

펜실베이니아의 급성 이표형 백혈병 임상 시험

급성 이표형 백혈병 관련 연구 6개가 펜실베이니아 내 여러 지역에서 참여자를 모집하고 있습니다.

펜실베이니아의 도시

공식 연구 텍스트(영어)

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

  • Lehigh Valley Hospital-Cedar Crest, Allentown
  • Geisinger Medical Center, Danville
  • Penn State Children's Hospital, Hershey
  • 외 2개
피험자 모집 중2상
365 Days · 모든 성별 · 2026. 9. 25. 업데이트됨 · NCT06317662

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

  • University of Pennsylvania, Philadelphia
피험자 모집 중1/2상
30 Days · 모든 성별 · 2026. 9. 16. 업데이트됨 · NCT04065399

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

  • Lehigh Valley Hospital-Cedar Crest, Allentown
  • Geisinger Medical Center, Danville
  • Penn State Children's Hospital, Hershey
  • 외 3개
피험자 모집 중3상
365 Days – 25 Years · 모든 성별 · 2026. 8. 25. 업데이트됨 · NCT03959085

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

  • Lehigh Valley Hospital-Cedar Crest, Allentown
  • Geisinger Medical Center, Danville
  • Penn State Children's Hospital, Hershey
  • 외 3개
피험자 모집 중1/2상
22세 이하 · 모든 성별 · 2026. 8. 25. 업데이트됨 · NCT04726241

Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

  • Children's Hospital of Philadelphia, Philadelphia
피험자 모집 중1상
1세 ~ 30세 · 모든 성별 · 2026. 8. 3. 업데이트됨 · NCT06177067

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

  • Children's Hospital of Philadelphia, Philadelphia
피험자 모집 중1상
1세 ~ 21세 · 모든 성별 · 2024. 12. 6. 업데이트됨 · NCT05476770

ClinicalTrials.gov 출처, 2026. 10. 5. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.